1
|
Liu S, Yang S, Blazekovic B, Li L, Zhang J, Wang Y. Bioactivities, Mechanisms, Production, and Potential Application of Bile Acids in Preventing and Treating Infectious Diseases. ENGINEERING 2024; 38:13-26. [DOI: 10.1016/j.eng.2023.11.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2025]
|
2
|
Cui K, Yang W, Liu Z, Liu G, Li D, Sun Y, He G, Ma S, Cao Y, Jiang X, Chevalier S, Cornelis P, Wei Q, Wang Y. Chenodeoxycholic Acid-Amikacin Combination Enhances Eradication of Staphylococcus aureus. Microbiol Spectr 2023; 11:e0243022. [PMID: 36625660 PMCID: PMC9927322 DOI: 10.1128/spectrum.02430-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Accepted: 12/07/2022] [Indexed: 01/11/2023] Open
Abstract
The rise of antibiotic resistance and dearth of novel antibiotics have posed a serious health crisis worldwide. In this study, we screened a combination of antibiotics and nonantibiotics providing a viable strategy to solve this issue by broadening the antimicrobial spectrum. We found that chenodeoxycholic acid (CDCA), a cholic acid derivative of the traditional Chinese medicine (TCM) Tanreqing (TRQ), synergizes with amikacin against Staphylococcus aureus in vitro, and this synergistic killing was effective against diverse methicillin-resistant S. aureus (MRSA) variants, including small-colony variants (SCVs), biofilm strains, and persisters. The CDCA-amikacin combination protects a mouse model from S. aureus infections. Mechanistically, CDCA increases the uptake of aminoglycosides in a proton motive force-dependent manner by dissipating the chemical potential and potentiates reactive oxygen species (ROS) generation by inhibiting superoxide dismutase activity. This work highlights the potential use of TCM components in treating S. aureus-associated infections and extend the use of aminoglycosides in eradicating Gram-positive pathogens. IMPORTANCE Multidrug resistance (MDR) is spreading globally with increasing speed. The search for new antibiotics is one of the key strategies in the fight against MDR. Antibiotic resistance breakers that may or may not have direct antibacterial action and can either be coadministered or conjugated with other antibiotics are being studied. To better expand the antibacterial spectrum of certain antibiotics, we identified one component from a traditional Chinese medicine, Tanreqing (TRQ), that increased the activity of aminoglycosides. We found that this so-called agent, chenodeoxycholic acid (CDCA), sensitizes Staphylococcus aureus to aminoglycoside killing and protects a mouse model from S. aureus infections. CDCA increases the uptake of aminoglycosides in a proton motive force-dependent manner by dissipating the chemical potential and potentiates ROS generation by inhibiting superoxide dismutase activity in S. aureus. Our work highlights the potential use of TCM or its effective components, such as CDCA, in treating antibiotic resistance-associated infections.
Collapse
Affiliation(s)
- Kaiyu Cui
- Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
| | - Weifeng Yang
- Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
| | - Zhiyuan Liu
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Guijian Liu
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Dongying Li
- Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yanan Sun
- Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
| | - Gaiying He
- Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
| | - Shuhua Ma
- Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yu Cao
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Xuefan Jiang
- Beijing University of Chinese Medicine, Beijing, China
| | - Sylvie Chevalier
- Normandy University, University of Rouen Normandy, Laboratory of Microbiology Signals and Microenvironment, Evreux, France
| | - Pierre Cornelis
- Normandy University, University of Rouen Normandy, Laboratory of Microbiology Signals and Microenvironment, Evreux, France
| | - Qing Wei
- Nanchang Institute of Technology, Nanchang, Jiangxi, China
| | - Yi Wang
- Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
3
|
Han XX, Tian YG, Liu XF, Zhao D, Du XH, Dong HR, Feng SX, Li JS. Network pharmacology combined with pharmacodynamics revealed the anti-inflammatory mechanism of Tanreqing capsule against acute-exacerbation chronic obstructive pulmonary disease. Sci Rep 2022; 12:13967. [PMID: 35978041 PMCID: PMC9385617 DOI: 10.1038/s41598-022-18326-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 08/09/2022] [Indexed: 11/27/2022] Open
Abstract
Acute-exacerbation chronic obstructive pulmonary disease (AECOPD) is mainly associated with acute respiratory tract infection. In recent years, a growing number of studies have found that Tanreqing capsule (TRQ) has a favorable anti-inflammatory effect. In this study, we used network pharmacology and pharmacodynamics to explore the molecular mechanism and effects of TRQ in AECOPD treatment. To further understand the molecular mechanism of TRQ in AECOPD treatment, we used the network pharmacology to predict components of TRQ, TRQ-related targets, AECOPD-related targets, and pathways. In addition, we used the cigarette-smoke/lipopolysaccharide -induced AECOPD experimental model in Sprague-Dawley rats (72 rats randomly divided into six groups [n = 12 each]: control, model, high-TRQ [TRQ-H], medium-TRQ [TRQ-M], low-TRQ, and dexamethasone [Dex]) to evaluate the therapeutic effects of TRQ and to verify the network pharmacology. We found that 59 overlapping targets based on component-and AECOPD-related targets were frequently involved in the advanced glycation end product-receptor for advanced glycation end product signaling pathway in diabetic complications, the phosphatidylinositol-3-kinase-protein kinase B signaling pathway, and the hypoxia-inducible factor 1 signaling pathway, which might play important roles in the anti-inflammatory mechanism of TRQ in AECOPD treatment. Moreover, TRQ groups exerted protective effects against AECOPD by reducing the infiltration of inflammatory cells. Meanwhile, TRQ-M and TRQ-H groups significantly downregulated or upregulated the expression of tumor necrosis factor, interleukin (IL) 6, C-reactive protein, IL10, and serum amyloid A, as key targets in network pharmacology, in the serum and bronchoalveolar lavage fluid to achieve anti-inflammatory efficacy. Our study showed that TRQ had better anti-inflammatory efficacy against AECOPD, and initially elucidated its molecular mechanism. Moreover, our study also provides a new strategy to explore effective mechanism of TRQ against AECOPD; and further studies are needed to validate the biological processes and pathways of TRQ against AECOPD.
Collapse
Affiliation(s)
- Xiao-Xiao Han
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, China
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China
| | - Yan-Ge Tian
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China
| | - Xue-Fang Liu
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China
| | - Di Zhao
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China
| | - Xue-Hang Du
- Shanghai Kaibao Pharmaceutical Co. Ltd, Shanghai, China
| | - Hao-Ran Dong
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China
| | - Su-Xiang Feng
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China.
| | - Jian-Sheng Li
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China.
- The First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
| |
Collapse
|
4
|
Li H, Jin J, Xue H, Li Y, Wang T, Shi R, Ma Y. Determination of multiple active constituents in Da-Huang-Xiao-Shi decoction using HPLC-LTQ-Orbitrap mass spectrometry: Application in comparing the differences in the formula and its constituent herbs. Biomed Chromatogr 2022; 36:e5324. [PMID: 34993982 DOI: 10.1002/bmc.5324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2021] [Revised: 12/21/2021] [Accepted: 12/22/2021] [Indexed: 11/10/2022]
Abstract
Da-Huang-Xiao-Shi decoction (DHXSD) is a traditional Chinese medicine formula and is used to treat cholestasis. In this study, we developed a reliable and comprehensive HPLC coupled with linear ion trap-Orbitrap mass spectrometry method for the separation and determination of 21 components including six alkaloids, five anthraquinones, three tannins, three terpenes, two iridoid glycosides, one organic acid, and one flavonoid in DHXSD. A C18 column was eluted by a gradient mobile phase containing at a flow rate of 1 mL/min. Detection was operated with electrospray ionization source in positive and negative ion modes using selective ion monitoring (SIM). The calibration curves for all analytes showed good linearity (r >0.9901), and the inter- and intra-day precision did not exceed 4.98%. The recoveries, repeatability, and stability were also within the acceptable limits. The method was successfully applied to determine multiple active constituents in DHXSD and its constituent herbs. Compared to Da Huang, the total contents of the five anthraquinones were significantly higher in DHXSD. However, the changes of components from Zhi Zi/Huang Bo were complicated in DHXSD. The study could serve as a fundamental reference for establishing comprehensive DHXSD quality control measures and be helpful to understand some compatibility laws of DHXSD.
Collapse
Affiliation(s)
- Hongyu Li
- Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Jingyi Jin
- Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Haoyu Xue
- Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Yuanyuan Li
- Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Tianming Wang
- Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Rong Shi
- Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China.,Science and Technology Experimental Center, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Yueming Ma
- Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| |
Collapse
|
5
|
Guo DA, Yao CL, Wei WL, Zhang JQ, Bi QR, Li JY, Khan I, Bauer R. Traditional Chinese medicines against COVID-19: A global overview. WORLD JOURNAL OF TRADITIONAL CHINESE MEDICINE 2022. [DOI: 10.4103/2311-8571.353502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
6
|
He YQ, Zhou CC, Yu LY, Wang L, Deng JL, Tao YL, Zhang F, Chen WS. Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms. Pharmacol Res 2021; 163:105224. [PMID: 33007416 PMCID: PMC7522693 DOI: 10.1016/j.phrs.2020.105224] [Citation(s) in RCA: 249] [Impact Index Per Article: 62.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 09/15/2020] [Accepted: 09/22/2020] [Indexed: 12/14/2022]
Abstract
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS) as common life-threatening lung diseases with high mortality rates are mostly associated with acute and severe inflammation in lungs. With increasing in-depth studies of ALI/ARDS, significant breakthroughs have been made, however, there are still no effective pharmacological therapies for treatment of ALI/ARDS. Especially, the novel coronavirus pneumonia (COVID-19) is ravaging the globe, and causes severe respiratory distress syndrome. Therefore, developing new drugs for therapy of ALI/ARDS is in great demand, which might also be helpful for treatment of COVID-19. Natural compounds have always inspired drug development, and numerous natural products have shown potential therapeutic effects on ALI/ARDS. Therefore, this review focuses on the potential therapeutic effects of natural compounds on ALI and the underlying mechanisms. Overall, the review discusses 159 compounds and summarizes more than 400 references to present the protective effects of natural compounds against ALI and the underlying mechanism.
Collapse
Affiliation(s)
- Yu-Qiong He
- Institute of Chinese Materia Madica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| | - Can-Can Zhou
- Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
| | - Lu-Yao Yu
- Institute of Chinese Materia Madica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| | - Liang Wang
- Institute of Chinese Materia Madica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| | - Jiu-Ling Deng
- Institute of Chinese Materia Madica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| | - Yu-Long Tao
- Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
| | - Feng Zhang
- Institute of Chinese Materia Madica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
| | - Wan-Sheng Chen
- Institute of Chinese Materia Madica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
| |
Collapse
|
7
|
Zhu WJ, Zhou X, Cao J, Shi Y. The effectiveness and safety of Tanreqing Injection combined with ganciclovir on the treatment of respiratory syncytial virus pneumonia in children: A protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2020; 99:e22356. [PMID: 32957408 PMCID: PMC7505387 DOI: 10.1097/md.0000000000022356] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Based on the Theory of Traditional Chinese Medicine, this study systematically evaluated the effectiveness and safety of Chinese medicine preparation Tanreqing injection combined with ganciclovir on the treatment of respiratory syncytial virus pneumonia in children, and provided new ideas and methods for the treatment of respiratory syncytial virus pneumonia (RSVP) in children. At the same time, it also studies the effectiveness and safety of the combination of Chinese and Western medicine on the treatment of related diseases from the direction of evidence-based medicine. METHODS The relevant literature was searched by the computer in the electronic network databases, the retrieved databases include Chinese database and English database, English database includes PubMed, Cochrane Library, Embase and Web of Science. Chinese database includes: CNKI, SinoMed, WangFang Date, VIP and other networks electronic full-text database, conducting a randomized controlled trial of Tanreqing Injection combined with ganciclovir (study group) and ganciclovir alone (control group) on the treatment of RSVP in children and the retrieval time limit is set from the establishment of each database to July 1, 2020. According to the inclusion and exclusion criteria, the literature is independently searched and screened by 2 researchers, and conducting the full-text retrieval and evaluation of the research to be included, and extracting the information and checking it after reading the full-text; In case of disagreement, a third researcher will be invited to participate, and the decision is made after discussion by the 3 researchers. They were using the bias risk assessment tool provided by the Cochrane Handbook for Systematic Reviews of Interventions 3.0.2 to evaluate the selected literature. They were using RevMan 5.3 statistical software to conduct statistical analysis. RESULTS This study will be carried out in full accordance with the steps of systematic review as required in the Cochrane Handbook for Systematic Reviews of Interventions. All research results will be published publicly in international academic journals with peer review. CONCLUSION After the meta-analysis of Tanreqing injection combined with ganciclovir on the treatment of RSVP in children, this paper will give a scientific and objective judgment on the effectiveness and safety of the combined use of Chinese and Western medicine on the treatment of RSVP in children, to provide evidence-based medical evidence for the clinical application, effectiveness and safety of Chinese and Western medicine combined on the treatment of RSVP in children. PROSPERO REGISTRATION NUMBER OSF platform, registration number: j2bz5.
Collapse
Affiliation(s)
- Wei-Jun Zhu
- Department of Pediatric, Haikou Hospital of the Maternal and Child Health, Guoxing Avenue
| | - Xuan Zhou
- Department of Pediatric, Haikou Hospital of the Maternal and Child Health, Guoxing Avenue
| | - Juan Cao
- Department of Pediatric, Hainan Modern Women and Children's Hospital, Qiongzhou Avenue, Qiongshan District, Haikou, Hainan, China
| | - Yu Shi
- Department of Pediatric, Hainan Modern Women and Children's Hospital, Qiongzhou Avenue, Qiongshan District, Haikou, Hainan, China
| |
Collapse
|
8
|
Ran M, Cha C, Xu Y, Zhang H, Yang Z, Li Z, Wang S. Traditional Chinese herbal medicine complex supplementation improves reproductive performance, serum biochemical parameters, and anti-oxidative capacity in periparturient dairy cows. Anim Biotechnol 2020; 33:647-656. [PMID: 32930627 DOI: 10.1080/10495398.2020.1819823] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
This study was conducted to investigate the effects of a traditional Chinese herbal medicine complex (TCHMC) on the productive performance of periparturient dairy cows. Eighteen non-lactating pregnant Holstein dairy cows with similar body conditions with 1 to 2 parity were randomly divided into three groups (n = 6), receiving a basal diet with 0 (CON group), 200 (T-200 group), and 300 (T-300 group) g TCHMC per day from 14 to 9 days prepartum. The results demonstrated that TCHMC treatments decreased the days of gestation, calving to first service, and calving to first visible estrus. Compared with CON at specific time points, TCHMC treatments increased the concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2), whereas progesterone (P4) and E2 concentrations decreased. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatine kinase (CK) concentrations were downregulated, whereas that of globulin (GLB) and immunoglobulin G (IgG) were upregulated by TCHMC treatments around the time of calving. Compared with CON and T-200 treatments, the T-300 treatment increased the serum concentrations of glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), catalase (CAT) and total antioxidant capacity (T-AOC) and decreased the malondialdehyde (MDA) concentration from 7 d prepartum to 21 d postpartum when. In addition, although TCHMC treatment had no effect on average birth weight, heart rate, respiratory rate, and body temperature of calves, the T-300 treatment increased serum albumin (ALB) and IgG concentrations in calves from 3 to 14 days postpartum. The addition of TCHMC used in the present study could serve as a potential effective strategy to improve the health and productive performance of periparturient dairy cows, and the optimal dose should be set at 300 g per day.
Collapse
Affiliation(s)
- Maoliang Ran
- College of Veterinary Medicine and College of Animal Science and Technology, Hunan Agricultural University, Changsha, China.,Hunan Provincial Key Laboratory for Genetic Improvement of Domestic Animal, Changsha, China
| | - Cheng Cha
- College of Veterinary Medicine and College of Animal Science and Technology, Hunan Agricultural University, Changsha, China
| | - Youtao Xu
- College of Veterinary Medicine and College of Animal Science and Technology, Hunan Agricultural University, Changsha, China
| | - Hongliang Zhang
- College of Veterinary Medicine and College of Animal Science and Technology, Hunan Agricultural University, Changsha, China
| | - Zecao Yang
- College of Veterinary Medicine and College of Animal Science and Technology, Hunan Agricultural University, Changsha, China
| | - Zhicai Li
- Hunan Deren Husbandry Company Ltd, Changsha, China
| | - Shuilian Wang
- College of Veterinary Medicine and College of Animal Science and Technology, Hunan Agricultural University, Changsha, China.,Hunan Engineering Technology Research Center of Veterinary Drugs, Changsha, China
| |
Collapse
|
9
|
Feng SX, Zhang HJ, Zhao D, Li RR, Du XH, Wang PY, Shu SN, Qu LB, Li JS. Chemical profiling and quantification of Tanreqing injection, a systematic quality control strategy equipped with UPLC-Q-Orbitrap fusion MS. J LIQ CHROMATOGR R T 2020. [DOI: 10.1080/10826076.2020.1723105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Su-Xiang Feng
- College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
- Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, by Henan and Education Ministry of P. R., Zhengzhou, Henan, China
| | - Hao-Jie Zhang
- College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
- Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, by Henan and Education Ministry of P. R., Zhengzhou, Henan, China
| | - Di Zhao
- College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
- Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, by Henan and Education Ministry of P. R., Zhengzhou, Henan, China
| | - Rong-Rong Li
- College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
- Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, by Henan and Education Ministry of P. R., Zhengzhou, Henan, China
| | - Xue-Hang Du
- Shanghai Kaibao Pharmaceutical Co. Ltd, Shanghai, China
| | - Pei-Yang Wang
- College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
- Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, by Henan and Education Ministry of P. R., Zhengzhou, Henan, China
| | - Sheng-Nan Shu
- College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
- Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, by Henan and Education Ministry of P. R., Zhengzhou, Henan, China
| | - Ling-Bo Qu
- College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou, China
| | - Jian-Sheng Li
- College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
- Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, by Henan and Education Ministry of P. R., Zhengzhou, Henan, China
| |
Collapse
|